Article
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Gynecologic oncology - 1 Jan 2024
Kahn Ryan M, Selenica Pier, Boerner Thomas, Roche Kara Long, Xiao Yonghong, Sia Tiffany Y, Maio Anna, Kemel Yelena, Sheehan Margaret, Salo-Mullen Erin, Breen Kelsey E, Zhou Qin, Iasonos Alexia, Grisham Rachel N, O'Cearbhaill Roisin E, Chi Dennis S, Berger Michael F, Kundra Ritika, Schultz Nikolaus, Ellenson Lora H, Stadler Zsofia K, Offit Kenneth, Mandelker Diana, Aghajanian Carol, Zamarin Dmitriy, Sabbatini Paul, Weigelt Britta, Liu Ying L
Abstract excerpt
OBJECTIVE: To define molecular features of ovarian cancer (OC) with germline pathogenic variants (PVs) in non-BRCA homologous recombination (HR) genes and analyze survival compared to BRCA1/2 and wildtype (WT) OC. METHODS: We included patients with OC undergoing tumor-normal sequencing (MSK-IMPACT) from 07/01/2015-12/31/2020, including germline assessment of BRCA1/2 and other HR genes ATM, BARD1, BRIP1, FANCA,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
